Details for Patent: 8,552,002
Which drugs does patent 8,552,002 protect, and when does it expire?
Patent 8,552,002 protects TRUSELTIQ and is included in one NDA.
This patent has forty-five patent family members in thirty-one countries.
Summary for Patent: 8,552,002
| Title: | Compounds and compositions as protein kinase inhibitors |
| Abstract: | The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease. |
| Inventor(s): | Qiang Ding, Nathanael Schiander Gray, Bing Li, Yi Liu, Taebo Sim, Tetsuo Uno, Guobao Zhang, Carole Pissot Soldermann, Werner Breitenstein, Guido Bold, Giorgio Caravatti, Pascal Furet, Vito Guagnano, Marc Lang, Paul William Manley, Joseph Schoepfer, Carsten Spanka |
| Assignee: | Novartis AG |
| Application Number: | US11/570,983 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,552,002 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,552,002
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-001 | May 28, 2021 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-002 | May 28, 2021 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,552,002
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0512324.5 | Jun 16, 2005 |
| PCT Information | |||
| PCT Filed | June 23, 2005 | PCT Application Number: | PCT/EP2005/006815 |
| PCT Publication Date: | January 05, 2006 | PCT Publication Number: | WO2006/000420 |
International Family Members for US Patent 8,552,002
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 050343 | ⤷ Start Trial | |||
| Austria | E520671 | ⤷ Start Trial | |||
| Australia | 2005256491 | ⤷ Start Trial | |||
| Australia | 2009213036 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
